Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

February 24, 2005



The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

ATACAND® (candesartan cilexetil) - Introduction, Dr. Cindy Lancaster, MS, MBA, JD, AstraZeneca(HTM) (PPT)

Background, Dr. James Young, MD, Cleveland Clinic Foundation (HTM) (PPT)

ACE Inhibitor Dosing Considerations in CHARM, Dr. John McMurrary, MD, Glasgow, Scotland, UK (HTM) (PPT)

CHARM Program, Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity - Efficacy, Dr. Marc Pfeffer, MD, PhD, Brigham and Women's Hospital (HTM) (PPT)

Safety of Candesartan in CHF, When Added to Evidence-based Doses of ACE Inhibitors, Dr. James Hainer, MD, MPH, AstraZeneca (HTM) (PPT)

Candesartan in HF Benefit/Risk, Dr. James Young, MD, Cleveland Clinic Foundation (HTM) (PPT)

Candesartan Support Slides, AstraZeneca (HTM) (PPT)

Questions to the Committee, FDA (HTM) (PPT)